Table 1.
Clinicopathological characteristics of patients
| Variables | n (%) |
|---|---|
| Sex | |
| Male | 16/25 (64) |
| Female | 9/25 (36) |
| Age (years) | |
| Range | 43–80 |
| Mean | 62.72 |
| Median | 59 |
| Primary adenocarcinoma sites | |
| Right colon | 3/25 (12) |
| Left colon | 7/25 (28) |
| Sigma | 9/25 (36) |
| Rectum | 6/25 (24) |
| Dukes’ Classification (Astler–Coller modification) | |
| A | 2 (8) |
| B | 2 (8) |
| C | 6 (24) |
| D | 15 (60) |
| Grading | |
| G1 | 6/25 (24) |
| G2 | 12/25 (48) |
| G3 | 7/25 (28) |
| Kras | |
| Wild type | 17/25 (68) |
| Mutated | 8/25 (32) |
| Lines of chemotherapy before DEBIRI | |
| 2 | 19/25 (76) |
| 3 | 6/25 (24) |
| Number of DEBIRI treatments | |
| 1 | 10/25 (40) |
| 2 | 11/25 (44) |
| 3 | 4/25 (16) |
Abbreviation: DEBIRI, drug-eluting beads with irinotecan.